title: Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?
authors.affiliation: Department of Medicine, University of Alberta, Edmonton, Canada.
authors.forename: S M
authors.initials: SM
authors.lastname: Cockfield
authors.forename: J
authors.initials: J
authors.lastname: Preiksaitis
authors.forename: E
authors.initials: E
authors.lastname: Harvey
authors.forename: C
authors.initials: C
authors.lastname: Jones
authors.forename: D
authors.initials: D
authors.lastname: Hebert
authors.forename: P
authors.initials: P
authors.lastname: Keown
authors.forename: P F
authors.initials: PF
authors.lastname: Halloran
mesh_terms: D000367:Age Factors; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D007115:Immunization Schedule; D007165:Immunosuppression Therapy / Q000379:methods*; D016030:Kidney Transplantation / Q000379:methods*; D008232:Lymphoproliferative Disorders / Q000209:etiology*; D008297:Male; D016853:Muromonab-CD3; D012189:Retrospective Studies; D012307:Risk Factors; D012737:Sex Factors; D014412:Tumor Virus Infections / Q000150:complications
chemical_list: D000911:Antibodies, Monoclonal; D000961:Antilymphocyte Serum; D016853:Muromonab-CD3